Previous 10 | Next 10 |
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...
ST. LOUIS, May 04, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, celebrates the achievements of the highly skilled electrophysiology team at The Heart Centre Rigshospitalet , Copenhag...
ST. LOUIS, April 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 first quarter on Tuesday, May 10, 2022 before th...
ST. LOUIS, March 24, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Poland’s National Institute of Cardiology , the leading clinical center of cardiology and card...
ST. LOUIS, March 09, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today is holding the grand opening of its new, 45,000-square-foot global headquarters facility in downtown St. Louis...
Solid Q4 beat overshadowed by prudent guidance that removes 4 "imminent" replacement system sales from FY2022 outlook. As per quarterly call, all have physician/administration support and remain “imminent”. Timing of closing the 4 "imminent" replacement sales will determ...
Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%. ...
Stereotaxis, Inc. (STXS) Q4 2021 Earnings Conference Call March 3, 2022, 10:00 AM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Adam Maeder - Piper Sandler Jason Wittes - Loop C...
Stereotaxis press release (NYSE:STXS): Q4 GAAP EPS of -$0.05 misses by $0.01. Revenue of $8.2M (+20.2% Y/Y) beats by $0.54M. For further details see: Stereotaxis GAAP EPS of -$0.05 misses by $0.01, revenue of $8.2M beats by $0.54M
ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021. “In 2021...
News, Short Squeeze, Breakout and More Instantly...
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Gene...
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation...
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac ...